Thymosin Beta Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The thymosin beta market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Thymosin beta is a family of small peptides involved in the polymerization of G-actin, and many other biological processes including cell migration and fibrosis. The rise in the incidence of corneal injuries is anticipated to drive the growth of the global thymosin beta market. For instance, according to the data published by the National Center for Biotechnology Information (NCBI in 2021, approximately 3% of all visits to the emergency department are due to eye trauma. The morbidity from corneal injuries can vary from minor and potentially insignificant to potentially vision-threatening. Further, exposure-related injuries to the cornea include burns from thermal, chemical and radiation sources. Moreover, ocular chemical burns are anticipated as an emergency, accounting for 11.5% to 22.1% of all ocular injuries. The incidence of corneal injuries is higher among people of working age between the ages of 20 and 29 years. Also, according to NCBI, thymosin beta promotes corneal wound healing and corneal inflammatory response. Thus, the rise in the incidence of corneal injuries is anticipated to drive the demand for the global thymosin beta market.

Also, the rise in the prevalence of brain injuries is anticipated to drive the growth of the global thymosin beta market. For instance, according to the data published by NCBI in 2021, approximately, 1.7 million people in the US suffer from traumatic brain injury, with adolescents between ages 15 and  19 years and adults age 65 and older amongst the most likely to sustain a traumatic brain injury. Moreover, the annual incidence is approximately 500 in 100,00 people. Thus, the rise in the incidence of brain injuries is anticipated to drive the demand for the global thymosin beta market.

Looking toward the demand for thymosin beta, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, NIH had conducted a phase 1a study of thymosin beta4 in healthy volunteers. This study aimed to evaluate the safety, tolerance, potential immunological reaction, and pharmacokinetics of single intravenous recombinant human thymosin in Chinese healthy volunteers. Moreover, 54 volunteers will be randomized to receive NL005 for 7 cohorts. Thus, such clinical trials are anticipated to drive the growth of the global thymosin beta market during the forecast period (2022-2028).

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- OriGene Technologies, Inc., Novus Biologicals, and Lifespan Biosciences Inc among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Thymosin Beta Market Report by Segment

By Type

• Skin Repair
• Corneal Injury
• Dry Eye
• Myocardial Injury
• Brain Injury
• Others

By Application

• Animals
• Humans